Epithalon vs Thymosin Alpha-1
Epithalon, also written Epitalon, is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from the pineal gland extract preparation Epithalamin, and reported to induce telomerase activity, modulate circadian and pineal gene expression and extend median lifespan in flies and rodents. Thymosin alpha-1, generic name thymalfasin, is a 28-amino-acid peptide derived from prothymosin alpha that acts largely through Toll-like receptor signalling on dendritic cells and monocytes, and is registered as a prescription immunomodulator in a number of countries. The two are paired because both are described as glandular peptides associated with ageing and immune function, and because a widely cited 2003 paper on pineal and thymic peptides is often read as testing both. It did not. No study has compared Epithalon with thymosin alpha-1, and their evidence bases differ in provenance, language, study design and the presence of negative results in a way that no side-by-side table can flatten.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered Epithalon and thymosin alpha-1 to the same subjects or compared them in parallel arms, in any model. Searches of PubMed and Europe PMC returned only reviews of short peptides and a small set of Russian-language gerontology papers on pineal and thymic peptide preparations, none of which used thymosin alpha-1. The record most often mistaken for a head-to-head is Khavinson and Morozov's 2003 report following 266 elderly subjects for six to eight years, which described reduced mortality in peptide-treated cohorts with the largest reduction in a combined group; that study used the thymic extract preparation Thymalin and the pineal extract preparation Epithalamin under an open, non-randomised design, so it tested neither the synthetic AEDG tetrapeptide nor thymosin alpha-1. Any comparison between the two compounds is therefore indirect and drawn from literatures that are not equivalent in kind: one is dominated by a single research group publishing largely in Russian-language journals with minimal independent replication and no registered randomised trial, the other consists of more than thirty controlled human trials including several large, well-conducted studies that returned null results.
Side by side.
| Epithalon | Thymosin Alpha-1 | |
|---|---|---|
| Evidence maturity | Early clinical | Approved drug |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 8 | 11 |
| Newest paper | 2026 | 2026 |
| Origin and class | A synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from a pineal gland extract preparation. Proposed mechanisms centre on telomerase induction, circadian and pineal gene expression, antioxidant activity and epigenetic chromatin effects. | A 28-amino-acid peptide derived from prothymosin alpha and originally isolated from thymic tissue, acting largely through Toll-like receptor signalling on dendritic cells and monocytes to influence T-cell differentiation, thymic output and cytokine balance. |
| Provenance of the evidence base | Dominated by a single research group, the St Petersburg Institute of Bioregulation and Gerontology, publishing largely in Russian-language journals such as Uspekhi Gerontologii and Byulleten Eksperimentalnoi Biologii i Meditsiny. Independent replication is very limited and the independent papers located are in vitro only. | More than thirty controlled human trials, with the great majority of randomised evidence originating from China and Italy. Multiple independent groups, multicentre designs and international journals are represented, and reviews note that geographic concentration as a limitation of the evidence. |
| Regulatory status | No approval anywhere. No registered, placebo-controlled randomised trial of the synthetic tetrapeptide has been published in the indexed literature. | Registered as a prescription immunomodulator in a number of countries, principally for chronic hepatitis B and as an adjuvant in sepsis and oncology. It is not approved by the FDA or EMA. |
| Strongest study design available | In vitro work in human cell lines, bovine and mouse oocytes and induced neurons, plus lifespan studies in Drosophila and SHR mice and a neuroendocrine study in aged rhesus monkeys. The one entry classed as human clinical measured senescence-marker protein expression in buccal epithelium and is published in Russian with an English abstract. | Multicentre double-blind placebo-controlled phase 3 randomised trials, Cochrane systematic review, and meta-analyses with trial sequential analysis. The largest, TESTS, randomised 1106 adults with sepsis across 22 centres. |
| Whether negative results exist | Essentially absent from the located record. The reported findings are consistently positive across telomerase, lifespan, circadian and antioxidant endpoints, which in a literature with minimal independent replication limits what can be inferred. | Present and substantial, which is itself a marker of a mature evidence base. TESTS found 28-day mortality of 23.4% versus 24.1% on placebo with a hazard ratio of 0.99 and no significant secondary outcome. A 508-patient double-blind trial in severe acute necrotising pancreatitis found infected pancreatic necrosis in 15.7% versus 18.1% of placebo, and a 690-patient cirrhosis study found similar outcomes with and without the peptide. |
| How pooled analyses behave | No meta-analysis of the tetrapeptide exists. Reviews of geroprotective peptides place it among investigational agents whose mechanistic rationale rests largely on preclinical data and conclude that validation through well-designed clinical trials is still required. | Pooled 28-day sepsis mortality favoured the peptide at an odds ratio of 0.73, but the effect disappeared in high-quality and multicentre subgroups, at odds ratios of 0.82 and 0.86 respectively, and trial sequential analysis indicated the cumulative sample remained inadequate. A Cochrane review reported a non-significant overall survival risk ratio of 1.21 in cancer. |
| Evidence specific to ageing | The stated rationale of the compound: telomerase induction in cultured human cells, lifespan increases of roughly 11 to 16 percent in Drosophila and about 12 percent maximum lifespan in female SHR mice, and restoration of evening melatonin output in aged monkeys. All are preclinical, and human pharmacokinetics, dose-response and long-term safety, including any oncological risk from telomerase induction, remain uncharacterised. | Peripheral to its evidence base. A 2025 narrative review summarised effects on T-cell differentiation, thymic output and vaccine responses in older adults, while noting that long-term efficacy and safety in geriatric populations remain unvalidated. There are no controlled human trials testing it as a longevity or healthy-ageing intervention. |
And what it does not.
Nothing in the published record compares these two peptides, and the asymmetry between their literatures is the most important thing a reader can take from the pairing. Thymosin alpha-1 has been through the apparatus that produces reliable knowledge: more than thirty controlled trials, a phase 3 study of 1106 patients, a Cochrane review, and meta-analyses whose favourable pooled signals dissolve when restricted to high-quality multicentre studies. That programme has produced clear negative results in sepsis, pancreatitis and hepatitis B cirrhosis, which is what a maturing evidence base looks like, and it has not tested the compound as an ageing intervention at all. Epithalon has not entered that apparatus. Its findings are largely preclinical, overwhelmingly from one research group, largely in Russian-language journals, with the small number of independent papers confined to cell culture, and no registered randomised trial of the synthetic tetrapeptide has been published. The frequently cited human longevity report used the pineal and thymic extract preparations Epithalamin and Thymalin under an open, non-randomised design, not the tetrapeptide and not thymosin alpha-1. Neither compound has controlled human evidence supporting use for healthy ageing, and for Epithalon even basic human pharmacokinetics, dose-response and any oncological risk associated with telomerase induction remain uncharacterised.
Common questions.
- Did the study on pineal and thymic peptides prolonging human life test thymosin alpha-1?
No. That 2003 report followed 266 elderly subjects for six to eight years using the thymic extract preparation Thymalin and the pineal extract preparation Epithalamin, in an open, non-randomised design. Thymalin is a thymic extract, not the 28-amino-acid thymosin alpha-1 peptide, and Epithalamin is a pineal extract rather than the synthetic AEDG tetrapeptide, so the study tested neither of the two compounds compared here.
- How much independent replication does the Epithalon literature have?
Very little. The evidence base is dominated by the St Petersburg Institute of Bioregulation and Gerontology and published largely in Russian-language journals. A small number of independent papers appeared between 2022 and 2025, including telomere-length work in human cell lines, retinal pigment epithelial wound healing and bovine oocyte maturation, and all of these are in vitro. No independent in vivo replication of the lifespan findings was located.
- Has thymosin alpha-1 failed any large randomised trial?
Yes, more than one, and this is central to reading its evidence base honestly. The phase 3 TESTS trial in 1106 adults with sepsis reported 28-day mortality of 23.4% versus 24.1% on placebo, a hazard ratio of 0.99 with no significant secondary or safety outcome. A 508-patient double-blind trial in predicted severe acute necrotising pancreatitis found no difference in infected pancreatic necrosis, and a 690-patient study in HBV-related compensated cirrhosis found similar outcomes with and without the peptide.
- Is either peptide an approved medicine?
Thymosin alpha-1 is registered as a prescription immunomodulator in a number of countries, principally for chronic hepatitis B and as an adjuvant in sepsis and oncology, but it is not approved by the FDA or EMA. Epithalon holds no approval anywhere, and no registered, placebo-controlled randomised trial of the synthetic tetrapeptide has been published in the indexed literature.
- Does either peptide have controlled human evidence for slowing ageing?
Neither does. The thymosin alpha-1 trial programme addresses sepsis, pancreatitis, hepatitis B, COPD exacerbations, COVID-19 and oncology, and a 2025 review noted that long-term efficacy and safety in geriatric populations remain unvalidated. The Epithalon geroprotective findings are preclinical, spanning cell culture, Drosophila, mice and aged monkeys, with no registered clinical trial of the tetrapeptide.
- Why does telomerase induction raise a safety question rather than settle one?
Because telomerase activity is also a feature of many cancers, and the published record does not resolve what sustained induction would mean in a human. The 2025 in vitro report attributed telomere lengthening to telomerase upregulation in normal cell lines and to alternative lengthening of telomeres in breast cancer lines. Human dose-response and any oncological risk from telomerase induction are listed as uncharacterised in the research record.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.